NeoGenomics Announces Board and Executive Changes
Ticker: NEO · Form: 8-K · Filed: Jan 10, 2025 · CIK: 1077183
Sentiment: neutral
Topics: management-change, board-of-directors, executive-compensation
TL;DR
NeoGenomics shakes up the board and exec comp - big changes coming?
AI Summary
On January 3, 2025, NeoGenomics, Inc. announced changes in its board of directors and executive compensation. The company filed an 8-K report detailing the departure of certain officers and the election of new directors. Specific details regarding compensatory arrangements for certain officers were also disclosed.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Board and executive changes can introduce uncertainty regarding future strategy and leadership stability.
Key Players & Entities
- NeoGenomics, Inc. (company) — Registrant
- January 3, 2025 (date) — Date of earliest event reported
- Nevada (jurisdiction) — State of incorporation
- Fort Myers, Florida (location) — Principal executive offices
FAQ
What specific roles have been affected by the departure of certain officers?
The filing indicates changes related to 'Departure of Directors or Certain Officers' and 'Appointment of Certain Officers' but does not specify the exact roles in this excerpt.
Were any new directors elected to the board?
Yes, the filing lists 'Election of Directors' as an item of information, indicating new directors were appointed.
What is the nature of the compensatory arrangements being disclosed?
The filing mentions 'Compensatory Arrangements of Certain Officers' as an item of information, suggesting details about executive pay will be provided.
What is NeoGenomics, Inc.'s state of incorporation?
NeoGenomics, Inc. is incorporated in Nevada.
When was the earliest event reported in this 8-K filing?
The earliest event reported is dated January 3, 2025.
Filing Stats: 1,119 words · 4 min read · ~4 pages · Grade level 11.1 · Accepted 2025-01-10 07:05:38
Key Financial Figures
- $0.001 — ange on which registered Common stock ($0.001 par value) NEO The Nasdaq Stock Market
- $23,913 — ruary 26, 2027 in exchange for a fee of $23,913 per month. The foregoing description
- $30 billion — s and markets representing in excess of $30 billion in revenues. Under his leadership, AZ c
- $1 billion — mercialized several brands in excess of $1 billion in sales. Mr. Zook was also responsible
- $850,000 — t Mr. Zook's annual base salary will be $850,000 to begin on April 1, 2025, and a target
- $8,000,000 — aggregate target value of approximately $8,000,000, to be granted at the discretion of the
Filing Documents
- neo-20250103.htm (8-K) — 39KB
- a101-neogenomicsxretiremen.htm (EX-10.1) — 98KB
- a102-specialadvisoragreeme.htm (EX-10.2) — 123KB
- a991-projectpearlxpressr.htm (EX-99.1) — 8KB
- a991-projectpearlxpressr001.jpg (GRAPHIC) — 258KB
- a991-projectpearlxpressr002.jpg (GRAPHIC) — 244KB
- 0001077183-25-000005.txt ( ) — 1137KB
- neo-20250103.xsd (EX-101.SCH) — 2KB
- neo-20250103_lab.xml (EX-101.LAB) — 22KB
- neo-20250103_pre.xml (EX-101.PRE) — 13KB
- neo-20250103_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On January 10, 2025, the Company issued a press release announcing Christopher Smith's retirement as the Company's Chief Executive Officer and the appointment of Tony Zook as the Chief Executive Officer, the entire text of which is attached hereto as Exhibit 99.1 and is incorporated by reference herein. Pursuant to the rules and regulations of the Securities and Exchange Commission, such exhibit and the information set forth therein and herein are deemed to be furnished and shall not be deemed to be filed.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (a) Not applicable (b) Not applicable (c) Not applicable (d) Exhibits. 10.1 Letter Agreement between NeoGenomics, Inc. and Christopher Smith, dated January 8, 2025 . 10.2 Special Advisor Agreement between NeoGenomics, Inc. and Christopher Smith, effective April 1, 2025. 99.1 Press Release of NeoGenomics, Inc., dated J anuary 10 , 202 5 . 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NEOGENOMICS, INC. Date: January 10, 2025 By: /s/ Jeffrey S. Sherman Name: Jeffrey S. Sherman Title: Chief Financial Officer